Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation
Mark J. Ratain, Javid J. Moslehi, Allen S. Lichter
Abstract
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Topics & Concepts
MedicineIbrutinibCardiotoxicityPharmacologyPostmarketing surveillanceTrastuzumabhERGInternal medicineIntensive care medicineOncologyAdverse effectChemotherapyCancerLeukemiaBreast cancerChronic lymphocytic leukemiaPotassium channelChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentChronic Myeloid Leukemia Treatments